Tigermed
Tigermed
Tigermed is a contract research company providing whole process clinical trial services for the R&D of pharmaceuticals.
Tigermed, founded in December, 2014 and headquartered in Hangzhou, is a contract research organization (CRO) focused on providing professional services for the entire process of clinical trials for new drug research. The founder is Ye Xiaoping. Listed on the SZSE on August 17, 2012, the company's major shareholders are Ye Xiaoping, Hong Kong Securities Clearing Co., Ltd and Cao Xiaochun. Rivals that have direct and indirect competition with Tigermed include Kintor, HitGen, Aprea Therapeutics, BridgeBio Pharma, etc.
- All
- News
- Analysis
- Research
Briefing Mar 24, 2021 05:40 PM
· Healthcare
Cancer cell therapy company raised CNY 500 million in D round
Briefing Feb 01, 2021 02:41 PM
· Healthcare
Bh009 new drug project independently researched and developed by Beihai biological Co., Ltd. was approved by China's clinical trials
In depth
Briefing Jan 27, 2021 06:29 PM
· Healthcare
Tiger pharmaceutical performance forecast: net profit in 2020 will increase by 100% - 115% year on year
Briefing Jan 08, 2021 09:36 AM
· Healthcare
Focus on high-throughput single-cell omics platform products, search for a reason to complete more than 100 million yuan round a financing
Research
Consumer Staples, Healthcare, TechnologyWIA2020 | Rising Tech Stars 2020: Global & China's 100
Dec 09, 2020 09:57 AM
Dec 09, 2020 09:39 AM
Research
Industrials, Financials, Consumer DiscretionaryTech for Global, Globalization Footprints of the Established and the New
May 29, 2020 08:30 PM
Research
Financials, Automotive, TechnologyLow-Carbon Industry Expansion - Key Studies From Chinese Companies
May 28, 2020 12:40 PM
Briefing Dec 30, 2020 05:28 PM
· Healthcare
Another protein component special medical food was approved, and the total number of approved products increased to 57
Briefing Dec 02, 2020 11:21 AM
· Healthcare
Improving service quality and enabling industrial innovation!
Briefing Nov 17, 2020 08:04 PM
· Healthcare
Plan to raise $4 billion! Jingdong health runs IPO
Briefing Nov 11, 2020 10:42 AM
· Healthcare
Drug Innovator Asieris Nabs CNY 700 Million Series D
Healthcare
Yunnan Baiyao's Revenue Rises 33%; Net Profit Falls 40% in 1Q 2021
On April 27, Yunnan Baiyao released a report for the first quarter of 2021 showing that the company's total operating revenue for the first quarter was 10.33 billion yuan, up 33.4% year-on-year; its operating profit was 880 million yuan, down 41.8% year-on-year; its net profit attributable to shareholders of the listed company was 760 million yuan.
Apr 30, 2021 02:07 AM
Healthcare
WIM2020: Insights on the Post-pandemic Outlook for the Healthcare Industry
The curtain came down on Dec 10 on the 'Healthtech Industry and COVID-19 Pandemic' Chapter at WIM 2020. Healthtech entrepreneurs and investors gathered to share insights on the outlook for the healthcare industry, covering topics like vaccination, AI healthcare, intelligent hardware, medical appliances and IVD.
Jan 07, 2021 02:10 PM
Briefing Sep 28, 2020 12:12 PM
· Healthcare
AI-Based Drug Research Platform XtalPi Closes Series C at USD 318.8 Mn
Briefing Sep 23, 2020 11:37 AM
· Healthcare
Top-Tier CDMO Heyuan China Closes Series C at over CNY 300 Mn
Briefing Sep 14, 2020 06:28 PM
· Healthcare
Nasdaq-listed Biotech ZLAB Passes the Hearing for Hong Kong IPO
In depth
Healthcare
WuXi AppTec: A Favorable Chinese Stock for MSCI and FTSE Russell
According to the latest quarterly index review, a Wuxi-based CRO company will be incorporated into the FTSE China A 50 Share Index. It has been considered a top holding by many MSCI China indexes for some time.
Jun 08, 2020 09:51 AM
Briefing Sep 14, 2020 06:22 PM
· Healthcare
Genor Biopharma Passes the Hearing for Hong Kong IPO
Briefing Sep 03, 2020 01:27 PM
· Healthcare
Tigermed Invests in Tongli Biomedical to Treat Parasitic Zoonoses
Briefing Aug 31, 2020 12:46 PM
· Healthcare
Chinese Biopharma Adlai Nortye Closes Series C at USD 100 Mn
Briefing Aug 07, 2020 07:51 PM
· Healthcare
TigerMed: New to be the Third Dual-listed CRO on HKEX and A-share
See more
Related Companies
EqualOcean Analysis
- Black Swans and Breakthroughs: China's Top 50 Innovative Public Firms in 2020
- More Room for the Medical Device Market to Grow in China
- Modern Chinese Medicine Maker Tasly Pharmaceutical: An Old Stock in a New Package?
- Haier Balances Smart Home Demand at Home and Overseas Trends
- TuSimple: Start with the Low-Hanging Fruit
EqualOcean is an information service provider and investment research company that aims to become a global platform for industrial innovation. Founded in February 2014 and headquartered in Beijing, with a client network covering over 50 countries, the firm provides comprehensive professional services, including industry research, investment analysis, innovation consulting, data products, corporate branding and international strategy.